AKI can be attributed to gentamicin due to its ability to induce apoptosis in renal cells. Therefore, patients who are prescribed gentamicin should undergo frequent monitoring of their renal function and drug concentration levels. While there are other potential causes of acute kidney injury, none of them are linked to aminoglycoside antibiotics.

Understanding the Difference between Acute Tubular Necrosis and Prerenal Uraemia

Acute kidney injury can be caused by various factors, including prerenal uraemia and acute tubular necrosis. It is important to differentiate between the two to determine the appropriate treatment. Prerenal uraemia occurs when the kidneys hold on to sodium to preserve volume, leading to decreased blood flow to the kidneys. On the other hand, acute tubular necrosis is caused by damage to the kidney tubules, which can be due to various factors such as toxins, infections, or ischemia.

To differentiate between the two, several factors can be considered. In prerenal uraemia, the urine sodium level is typically less than 20 mmol/L, while in acute tubular necrosis, it is usually greater than 40 mmol/L. The urine osmolality is also higher in prerenal uraemia, typically above 500 mOsm/kg, while in acute tubular necrosis, it is usually below 350 mOsm/kg. The fractional sodium excretion is less than 1% in prerenal uraemia, while it is greater than 1% in acute tubular necrosis. Additionally, the response to fluid challenge is typically good in prerenal uraemia, while it is poor in acute tubular necrosis.

Other factors that can help differentiate between the two include the serum urea:creatinine ratio, fractional urea excretion, urine:plasma osmolality, urine:plasma urea, specific gravity, and urine sediment. By considering these factors, healthcare professionals can accurately diagnose and treat acute kidney injury.

Idiopathic membranous glomerulonephritis is believed to be associated with anti-phospholipase A2 antibodies. This condition is a common cause of nephrotic syndrome in adults, and since the patient has no other relevant medical history, an idiopathic cause is likely. To confirm the diagnosis, measuring anti-phospholipase A2 levels is recommended.

Testing for ASOT would suggest post-streptococcal glomerulonephritis (PSGN), which is more common in children and typically presents with an acute nephritic picture rather than nephrotic syndrome. Therefore, this is not the most likely diagnosis.

While dyslipidaemia is commonly found in nephrotic syndrome, confirming it would not help confirm the suspected diagnosis of idiopathic membranous glomerulonephritis.

Although acute kidney injury (AKI) can occur in individuals with nephrotic syndrome, assessing renal function is unlikely to help diagnose membranous glomerulonephritis.

While assessing the protein content in a sample may be useful in diagnosing nephrotic syndrome, it is not specific to membranous glomerulonephritis.

Membranous glomerulonephritis is the most common type of glomerulonephritis in adults and is the third leading cause of end-stage renal failure. It typically presents with proteinuria or nephrotic syndrome. A renal biopsy will show a thickened basement membrane with subepithelial electron dense deposits, creating a spike and dome appearance. The condition can be caused by various factors, including infections, malignancy, drugs, autoimmune diseases, and idiopathic reasons.

Management of membranous glomerulonephritis involves the use of ACE inhibitors or ARBs to reduce proteinuria and improve prognosis. Immunosuppression may be necessary for patients with severe or progressive disease, but many patients spontaneously improve. Corticosteroids alone are not effective, and a combination of corticosteroid and another agent such as cyclophosphamide is often used. Anticoagulation may be considered for high-risk patients.

The prognosis for membranous glomerulonephritis follows the rule of thirds: one-third of patients experience spontaneous remission, one-third remain proteinuric, and one-third develop end-stage renal failure. Good prognostic factors include female sex, young age at presentation, and asymptomatic proteinuria of a modest degree at the time of diagnosis.

Renal stones are predominantly made up of calcium phosphate, and individuals with renal tubular acidosis are at a higher risk of developing them. Uric acid stones, which make up only 5-10% of cases, are often associated with malignancies.

Renal stones can be classified into different types based on their composition. Calcium oxalate stones are the most common, accounting for 85% of all calculi. These stones are formed due to hypercalciuria, hyperoxaluria, and hypocitraturia. They are radio-opaque and may also bind with uric acid stones. Cystine stones are rare and occur due to an inherited recessive disorder of transmembrane cystine transport. Uric acid stones are formed due to purine metabolism and may precipitate when urinary pH is low. Calcium phosphate stones are associated with renal tubular acidosis and high urinary pH. Struvite stones are formed from magnesium, ammonium, and phosphate and are associated with chronic infections. The pH of urine can help determine the type of stone present, with calcium phosphate stones forming in normal to alkaline urine, uric acid stones forming in acidic urine, and struvate stones forming in alkaline urine. Cystine stones form in normal urine pH.

The kidneys produce renin in their juxtaglomerular cells, which plays a crucial role in the renin-angiotensin-aldosterone system. This enzyme converts angiotensinogen into angiotensin I through a hydrolysis reaction. More information on this system can be found below.

Another important enzyme in this system is angiotensin-converting-enzyme (ACE), which is primarily located in the lungs but can also be found in smaller quantities in endothelial cells of the vasculature and kidney epithelial cells. ACE converts angiotensin I to angiotensin II and is the target of ACE inhibitors.

Carbonic anhydrase is an enzyme that facilitates the reaction between water and carbon dioxide to form bicarbonate, and it can also catalyze the reverse reaction. Carbonic anhydrase inhibitors target this enzyme.

Cyclooxygenase-2 (COX-2) is involved in the synthesis of prostaglandins, and NSAIDs are believed to work by inhibiting both COX-1 and COX-2 enzymes.

The renin-angiotensin-aldosterone system is a complex system that regulates blood pressure and fluid balance in the body. The adrenal cortex is divided into three zones, each producing different hormones. The zona glomerulosa produces mineralocorticoids, mainly aldosterone, which helps regulate sodium and potassium levels in the body. Renin is an enzyme released by the renal juxtaglomerular cells in response to reduced renal perfusion, hyponatremia, and sympathetic nerve stimulation. It hydrolyses angiotensinogen to form angiotensin I, which is then converted to angiotensin II by angiotensin-converting enzyme in the lungs. Angiotensin II has various actions, including causing vasoconstriction, stimulating thirst, and increasing proximal tubule Na+/H+ activity. It also stimulates aldosterone and ADH release, which causes retention of Na+ in exchange for K+/H+ in the distal tubule.

The superior and inferior hypogastric plexuses are responsible for providing sympathetic innervation to the bladder, which helps maintain detrusor capacity by preventing parasympathetic contraction of the bladder.

Bladder Anatomy and Innervation

The bladder is a three-sided pyramid-shaped organ located in the pelvic cavity. Its apex points towards the symphysis pubis, while the base lies anterior to the rectum or vagina. The bladder’s inferior aspect is retroperitoneal, while the superior aspect is covered by peritoneum. The trigone, the least mobile part of the bladder, contains the ureteric orifices and internal urethral orifice. The bladder’s blood supply comes from the superior and inferior vesical arteries, while venous drainage occurs through the vesicoprostatic or vesicouterine venous plexus. Lymphatic drainage occurs mainly to the external iliac and internal iliac nodes, with the obturator nodes also playing a role. The bladder is innervated by parasympathetic nerve fibers from the pelvic splanchnic nerves and sympathetic nerve fibers from L1 and L2 via the hypogastric nerve plexuses. The parasympathetic fibers cause detrusor muscle contraction, while the sympathetic fibers innervate the trigone muscle. The external urethral sphincter is under conscious control, and voiding occurs when the rate of neuronal firing to the detrusor muscle increases.

Desmopressin is an effective treatment for central diabetes insipidus, which is a rare condition caused by damage or dysfunction of the posterior pituitary gland resulting in a lack of ADH production. Carbimazole is used to treat hyperthyroidism, while goserelin is used to treat prostate cancer. Indapamide, a thiazide-like diuretic, is used to manage hypertension and heart failure.

Diabetes insipidus is a medical condition that can be caused by either a decreased secretion of antidiuretic hormone (ADH) from the pituitary gland (cranial DI) or an insensitivity to ADH (nephrogenic DI). Cranial DI can be caused by various factors such as head injury, pituitary surgery, and infiltrative diseases like sarcoidosis. On the other hand, nephrogenic DI can be caused by genetic factors, electrolyte imbalances, and certain medications like lithium and demeclocycline. The common symptoms of DI are excessive urination and thirst. Diagnosis is made through a water deprivation test and checking the osmolality of the urine. Treatment options include thiazides and a low salt/protein diet for nephrogenic DI, while central DI can be treated with desmopressin.

The Gell and Coombs classification of hypersensitivity reactions categorizes reactions into four types. Type 2 reactions involve the binding of IgG and IgM to a cell, resulting in cell death. Examples of type 2 reactions include Goodpasture syndrome, haemolytic disease of the newborn, and rheumatic fever.

Allergic rhinitis is an instance of a type 1 (immediate) reaction, which is IgE mediated. It is a hypersensitivity to a previously harmless substance.

Type 3 reactions are mediated by immune complexes, with rheumatoid arthritis being an example of a type 3 hypersensitivity reaction.

Type 4 (delayed) reactions are mediated by T lymphocytes and cause contact dermatitis.

Anti-glomerular basement membrane (GBM) disease, previously known as Goodpasture’s syndrome, is a rare form of small-vessel vasculitis that is characterized by both pulmonary haemorrhage and rapidly progressive glomerulonephritis. This condition is caused by anti-GBM antibodies against type IV collagen and is more common in men, with a bimodal age distribution. Goodpasture’s syndrome is associated with HLA DR2.

The features of this disease include pulmonary haemorrhage and rapidly progressive glomerulonephritis, which can lead to acute kidney injury. Nephritis can result in proteinuria and haematuria. Renal biopsy typically shows linear IgG deposits along the basement membrane, while transfer factor is raised secondary to pulmonary haemorrhages.

Management of anti-GBM disease involves plasma exchange (plasmapheresis), steroids, and cyclophosphamide. One of the main complications of this condition is pulmonary haemorrhage, which can be exacerbated by factors such as smoking, lower respiratory tract infection, pulmonary oedema, inhalation of hydrocarbons, and young males.

Thiazide diuretics, specifically bendroflumethiazide, can be used to decrease calcium excretion and stone formation in patients with hypercalciuria and renal stones. The patient’s urinary calcium levels indicate hypercalciuria, which can be managed with thiazide diuretics. Bumetanide and furosemide, both loop diuretics, are not effective in managing hypercalciuria and renal stones. Denosumab, an antibody used for hypercalcaemia associated with malignancy, is not used in the management of renal stones.

Management and Prevention of Renal Stones

Renal stones, also known as kidney stones, can cause severe pain and discomfort. The British Association of Urological Surgeons (BAUS) has published guidelines on the management of acute ureteric/renal colic. Initial management includes the use of NSAIDs as the analgesia of choice for renal colic, with caution taken when prescribing certain NSAIDs due to increased risk of cardiovascular events. Alpha-adrenergic blockers are no longer routinely recommended, but may be beneficial for patients amenable to conservative management. Initial investigations include urine dipstick and culture, serum creatinine and electrolytes, FBC/CRP, and calcium/urate levels. Non-contrast CT KUB is now recommended as the first-line imaging for all patients, with ultrasound having a limited role.

Most renal stones measuring less than 5 mm in maximum diameter will pass spontaneously within 4 weeks. However, more intensive and urgent treatment is indicated in the presence of ureteric obstruction, renal developmental abnormality, and previous renal transplant. Treatment options include lithotripsy, nephrolithotomy, ureteroscopy, and open surgery. Shockwave lithotripsy involves generating a shock wave externally to the patient, while ureteroscopy involves passing a ureteroscope retrograde through the ureter and into the renal pelvis. Percutaneous nephrolithotomy involves gaining access to the renal collecting system and performing intra corporeal lithotripsy or stone fragmentation. The preferred treatment option depends on the size and complexity of the stone.

Prevention of renal stones involves lifestyle modifications such as high fluid intake, low animal protein and salt diet, and thiazide diuretics to increase distal tubular calcium resorption. Calcium stones may also be due to hypercalciuria, which can be managed with thiazide diuretics. Oxalate stones can be managed with cholestyramine and pyridoxine, while uric acid stones can be managed with allopurinol and urinary alkalinization with oral bicarbonate.

The cause of membranoproliferative glomerulonephritis, type 2, is persistent activation of the alternative complement pathway, which leads to kidney damage. This condition is characterized by IgG antibodies, known as C3 nephritic factor, that target C3 convertase. In contrast, Goodpasture’s syndrome is associated with anti-GBM antibodies, while rapidly progressive glomerulonephritis may involve cell-mediated injury. Immune complex-mediated glomerulopathies, such as SLE and post-streptococcal glomerulonephritis, are caused by circulating immune complexes, while non-immunologic kidney damage is seen in diabetic nephropathy and hypertensive nephropathy.

Understanding Membranoproliferative Glomerulonephritis

Membranoproliferative glomerulonephritis, also known as mesangiocapillary glomerulonephritis, is a kidney disease that can present as nephrotic syndrome, haematuria, or proteinuria. Unfortunately, it has a poor prognosis. There are three types of this disease, with type 1 accounting for 90% of cases. It is caused by cryoglobulinaemia and hepatitis C, and can be diagnosed through a renal biopsy that shows subendothelial and mesangium immune deposits of electron-dense material resulting in a ‘tram-track’ appearance under electron microscopy.

Type 2, also known as ‘dense deposit disease’, is caused by partial lipodystrophy and factor H deficiency. It is characterized by persistent activation of the alternative complement pathway, low circulating levels of C3, and the presence of C3b nephritic factor in 70% of cases. This factor is an antibody to alternative-pathway C3 convertase (C3bBb) that stabilizes C3 convertase. A renal biopsy for type 2 shows intramembranous immune complex deposits with ‘dense deposits’ under electron microscopy.

Type 3 is caused by hepatitis B and C. While steroids may be effective in managing this disease, it is important to note that the prognosis for all types of membranoproliferative glomerulonephritis is poor. Understanding the different types and their causes can help with diagnosis and management of this serious kidney disease.

Potter sequence is a condition characterized by oligohydramnios, which can be caused by renal diseases like bilateral renal agenesis, ARPKD, and ADPKD. This condition often leads to pulmonary hypoplasia, clubbed feet, and cranial anomalies in neonates. However, oesophageal atresia, which causes polyhydramnios, is not associated with Potter sequence.

Understanding Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal recessive polycystic kidney disease (ARPKD) is a rare genetic disorder that affects the kidneys and liver. Unlike the more common autosomal dominant polycystic kidney disease (ADPKD), ARPKD is caused by a defect in a gene on chromosome 6 that encodes fibrocystin, a protein essential for normal renal tubule development.

ARPKD is typically diagnosed during prenatal ultrasound or in early infancy when abdominal masses and renal failure are observed. Newborns with ARPKD may also exhibit features consistent with Potter’s syndrome due to oligohydramnios. The disease progresses rapidly, and end-stage renal failure usually develops in childhood. In addition to kidney involvement, patients with ARPKD often have liver complications such as portal and interlobular fibrosis.

Renal biopsy is a common diagnostic tool for ARPKD, which typically shows multiple cylindrical lesions at right angles to the cortical surface. Early diagnosis and management are crucial in improving outcomes for patients with ARPKD.

The correct treatment for stabilizing the cardiac membrane in a patient with hyperkalaemia and ECG changes, such as peaked T waves and loss of P waves, is IV calcium gluconate. This is the first-line treatment option, as it can effectively stabilize the cardiac membrane and prevent arrhythmias. Other treatment options, such as calcium resonium, combined insulin/dextrose infusion, and nebulised salbutamol, can be used to treat hyperkalaemia, but only after IV calcium gluconate has been given.

Managing Hyperkalaemia: A Step-by-Step Guide

Hyperkalaemia is a serious condition that can lead to life-threatening arrhythmias if left untreated. To manage hyperkalaemia, it is important to address any underlying factors that may be contributing to the condition, such as acute kidney injury, and to stop any aggravating drugs, such as ACE inhibitors. Treatment can be categorised based on the severity of the hyperkalaemia, which is classified as mild, moderate, or severe based on the patient’s potassium levels.

ECG changes are also important in determining the appropriate management for hyperkalaemia. Peaked or ‘tall-tented’ T waves, loss of P waves, broad QRS complexes, and a sinusoidal wave pattern are all associated with hyperkalaemia and should be evaluated in all patients with new hyperkalaemia.

The principles of treatment modalities for hyperkalaemia include stabilising the cardiac membrane, shifting potassium from extracellular to intracellular fluid compartments, and removing potassium from the body. IV calcium gluconate is used to stabilise the myocardium, while insulin/dextrose infusion and nebulised salbutamol can be used to shift potassium from the extracellular to intracellular fluid compartments. Calcium resonium, loop diuretics, and dialysis can be used to remove potassium from the body.

In practical terms, all patients with severe hyperkalaemia or ECG changes should receive emergency treatment, including IV calcium gluconate to stabilise the myocardium and insulin/dextrose infusion to shift potassium from the extracellular to intracellular fluid compartments. Other treatments, such as nebulised salbutamol, may also be used to temporarily lower serum potassium levels. Further management may involve stopping exacerbating drugs, treating any underlying causes, and lowering total body potassium through the use of calcium resonium, loop diuretics, or dialysis.

The Loop of Henle creates the highest osmolarity in the nephron, while the proximal tubule absorbs most of the water. The tip of the papilla has the greatest osmolarity, which is also the maximum osmolarity that urine can attain after water absorption in the collecting ducts. The medulla of the kidney facilitates water reabsorption in the collecting ducts due to the osmotic gradient formed by the Loops of Henle.

The Loop of Henle and its Role in Renal Physiology

The Loop of Henle is a crucial component of the renal system, located in the juxtamedullary nephrons and running deep into the medulla. Approximately 60 litres of water containing 9000 mmol sodium enters the descending limb of the loop of Henle in 24 hours. The osmolarity of fluid changes and is greatest at the tip of the papilla. The thin ascending limb is impermeable to water, but highly permeable to sodium and chloride ions. This loss means that at the beginning of the thick ascending limb the fluid is hypo osmotic compared with adjacent interstitial fluid. In the thick ascending limb, the reabsorption of sodium and chloride ions occurs by both facilitated and passive diffusion pathways. The loops of Henle are co-located with vasa recta, which have similar solute compositions to the surrounding extracellular fluid, preventing the diffusion and subsequent removal of this hypertonic fluid. The energy-dependent reabsorption of sodium and chloride in the thick ascending limb helps to maintain this osmotic gradient. Overall, the Loop of Henle plays a crucial role in regulating the concentration of solutes in the renal system.

When blood pressure drops below the level at which the kidney can regulate its blood flow, hypovolemic shock can lead to a reduction in renal blood flow. This can cause an increase in specific gravity as the body tries to retain water to maintain blood volume.

The Loop of Henle and its Role in Renal Physiology

The Loop of Henle is a crucial component of the renal system, located in the juxtamedullary nephrons and running deep into the medulla. Approximately 60 litres of water containing 9000 mmol sodium enters the descending limb of the loop of Henle in 24 hours. The osmolarity of fluid changes and is greatest at the tip of the papilla. The thin ascending limb is impermeable to water, but highly permeable to sodium and chloride ions. This loss means that at the beginning of the thick ascending limb the fluid is hypo osmotic compared with adjacent interstitial fluid. In the thick ascending limb, the reabsorption of sodium and chloride ions occurs by both facilitated and passive diffusion pathways. The loops of Henle are co-located with vasa recta, which have similar solute compositions to the surrounding extracellular fluid, preventing the diffusion and subsequent removal of this hypertonic fluid. The energy-dependent reabsorption of sodium and chloride in the thick ascending limb helps to maintain this osmotic gradient. Overall, the Loop of Henle plays a crucial role in regulating the concentration of solutes in the renal system.

Salbutamol reduces serum potassium levels by acting as a β2 agonist when administered through nebulisation or intravenous routes.

Drugs and their Effects on Potassium Levels

Many commonly prescribed drugs have the potential to alter the levels of potassium in the bloodstream. Some drugs can decrease the amount of potassium in the blood, while others can increase it.

Drugs that can decrease serum potassium levels include thiazide and loop diuretics, as well as acetazolamide. On the other hand, drugs that can increase serum potassium levels include ACE inhibitors, angiotensin-2 receptor blockers, spironolactone, and potassium-sparing diuretics like amiloride and triamterene. Additionally, taking potassium supplements like Sando-K or Slow-K can also increase potassium levels in the blood.

It’s important to note that the above list does not include drugs used to temporarily decrease serum potassium levels for patients with hyperkalaemia, such as salbutamol or calcium resonium.

Overall, it’s crucial for healthcare providers to be aware of the potential effects of medications on potassium levels and to monitor patients accordingly.

Autosomal dominant polycystic kidney disease (ADPKD) is a commonly inherited kidney disease that affects 1 in 1,000 Caucasians. The disease is caused by mutations in two genes, PKD1 and PKD2, which produce polycystin-1 and polycystin-2 respectively. ADPKD type 1 accounts for 85% of cases, while ADPKD type 2 accounts for 15% of cases. ADPKD type 1 is caused by a mutation in the PKD1 gene on chromosome 16, while ADPKD type 2 is caused by a mutation in the PKD2 gene on chromosome 4. ADPKD type 1 tends to present with renal failure earlier than ADPKD type 2.

To screen for ADPKD in relatives of affected individuals, an abdominal ultrasound is recommended. The diagnostic criteria for ultrasound include the presence of two cysts, either unilateral or bilateral, if the individual is under 30 years old. If the individual is between 30-59 years old, two cysts in both kidneys are required for diagnosis. If the individual is over 60 years old, four cysts in both kidneys are necessary for diagnosis.

For some patients with ADPKD, tolvaptan, a vasopressin receptor 2 antagonist, may be an option to slow the progression of cyst development and renal insufficiency. However, NICE recommends tolvaptan only for adults with ADPKD who have chronic kidney disease stage 2 or 3 at the start of treatment, evidence of rapidly progressing disease, and if the company provides it with the agreed discount in the patient access scheme.

The proximal convoluted tubule is responsible for the majority of renal phosphate reabsorption. This occurs through co-transport with sodium and up to two thirds of filtered water. The thin ascending limb of the Loop of Henle is impermeable to water but highly permeable to sodium and chloride, while reabsorption of these ions occurs in the thick ascending limb. Parathyroid hormone is most effective at the proximal convoluted tubule due to its role in regulating phosphate reabsorption.

The Loop of Henle and its Role in Renal Physiology

The Loop of Henle is a crucial component of the renal system, located in the juxtamedullary nephrons and running deep into the medulla. Approximately 60 litres of water containing 9000 mmol sodium enters the descending limb of the loop of Henle in 24 hours. The osmolarity of fluid changes and is greatest at the tip of the papilla. The thin ascending limb is impermeable to water, but highly permeable to sodium and chloride ions. This loss means that at the beginning of the thick ascending limb the fluid is hypo osmotic compared with adjacent interstitial fluid. In the thick ascending limb, the reabsorption of sodium and chloride ions occurs by both facilitated and passive diffusion pathways. The loops of Henle are co-located with vasa recta, which have similar solute compositions to the surrounding extracellular fluid, preventing the diffusion and subsequent removal of this hypertonic fluid. The energy-dependent reabsorption of sodium and chloride in the thick ascending limb helps to maintain this osmotic gradient. Overall, the Loop of Henle plays a crucial role in regulating the concentration of solutes in the renal system.

The level with L2 is where the renal arteries typically branch off from the aorta.

Anatomy of the Renal Arteries

The renal arteries are blood vessels that supply the kidneys with oxygenated blood. They are direct branches off the aorta and enter the kidney at the hilum. The right renal artery is longer than the left renal artery. The renal vein, artery, and pelvis also enter the kidney at the hilum.

The right renal artery is related to the inferior vena cava, right renal vein, head of the pancreas, and descending part of the duodenum. On the other hand, the left renal artery is related to the left renal vein and tail of the pancreas.

In some cases, there may be accessory arteries, mainly on the left side. These arteries usually pierce the upper or lower part of the kidney instead of entering at the hilum.

Before reaching the hilum, each renal artery divides into four or five segmental branches that supply each pyramid and cortex. These segmental branches then divide within the sinus into lobar arteries. Each vessel also gives off small inferior suprarenal branches to the suprarenal gland, ureter, and surrounding tissue and muscles.

The correct answer is Henoch-Schonlein purpura, which is a type of small vessel vasculitis mediated by IgA. It typically affects children who have recently had a viral infection and is characterized by a purplish rash on the buttocks and flexor surfaces of the upper and lower limbs. Treatment is mainly supportive.

Granulomatosis with polyangitis is not the correct answer as it is a different type of vasculitis that is not IgA-mediated. It usually presents with a triad of upper respiratory symptoms (such as sinusitis and epistaxis), lower respiratory tract symptoms (like cough and haemoptysis), and glomerulonephritis (which causes haematuria and proteinuria leading to frothy urine).

Kawasaki disease is another type of vasculitis that affects children, but it is a medium vessel vasculitis triggered by unknown mechanisms. The classic presentation includes prolonged fever (lasting over 5 days) and redness of the eyes, hands, and feet. There may also be mucosal involvement with the characteristic strawberry tongue.

Minimal change disease is the most common cause of nephrotic syndrome in young children. It can also be associated with a preceding viral infection, but it does not present with a purplish rash. Instead, it is characterized by facial swelling and frothy urine.

Understanding Henoch-Schonlein Purpura

Henoch-Schonlein purpura (HSP) is a type of small vessel vasculitis that is mediated by IgA. It is often associated with IgA nephropathy, also known as Berger’s disease. HSP is commonly observed in children following an infection.

The condition is characterized by a palpable purpuric rash, which is accompanied by localized oedema over the buttocks and extensor surfaces of the arms and legs. Other symptoms include abdominal pain and polyarthritis. In some cases, patients may also experience haematuria and renal failure, which are indicative of IgA nephropathy.

Treatment for HSP typically involves analgesia for arthralgia. While there is inconsistent evidence for the use of steroids and immunosuppressants, supportive care is generally recommended for patients with nephropathy. The prognosis for HSP is usually excellent, particularly in children without renal involvement. However, it is important to monitor blood pressure and urinalysis to detect any signs of progressive renal involvement. Approximately one-third of patients may experience a relapse.

In summary, Henoch-Schonlein purpura is a self-limiting condition that is often seen in children following an infection. While the symptoms can be uncomfortable, the prognosis is generally good. However, it is important to monitor patients for any signs of renal involvement and provide appropriate supportive care.

The RAS is a hormone system that regulates plasma sodium concentration and arterial blood pressure. When plasma sodium concentration is low or renal blood flow is reduced due to low blood pressure, juxtaglomerular cells in the kidneys convert prorenin to renin, which is secreted into circulation. Renin acts on angiotensinogen to form angiotensin I, which is then converted to angiotensin II by ACE found in the lungs and epithelial cells of the kidneys. Angiotensin II is a potent vasoactive peptide that constricts arterioles, increasing arterial blood pressure and stimulating aldosterone secretion from the adrenal cortex. Aldosterone causes the kidneys to reabsorb sodium ions from tubular fluid back into the blood while excreting potassium ions in urine.

The renin-angiotensin-aldosterone system is a complex system that regulates blood pressure and fluid balance in the body. The adrenal cortex is divided into three zones, each producing different hormones. The zona glomerulosa produces mineralocorticoids, mainly aldosterone, which helps regulate sodium and potassium levels in the body. Renin is an enzyme released by the renal juxtaglomerular cells in response to reduced renal perfusion, hyponatremia, and sympathetic nerve stimulation. It hydrolyses angiotensinogen to form angiotensin I, which is then converted to angiotensin II by angiotensin-converting enzyme in the lungs. Angiotensin II has various actions, including causing vasoconstriction, stimulating thirst, and increasing proximal tubule Na+/H+ activity. It also stimulates aldosterone and ADH release, which causes retention of Na+ in exchange for K+/H+ in the distal tubule.

Lupus nephritis is characterized by proliferative ‘wire-loop’ glomerular histology, proteinuria, and systemic symptoms. This condition occurs when autoimmune processes in SLE cause inflammation and damage to the glomeruli. Symptoms may include oedema, myalgia, arthralgia, hypertension, and foamy-appearing urine due to high levels of protein. Acute tubular necrosis primarily affects the tubules and does not typically present with proteinuria. Congestive heart failure and IgA nephropathy can cause proteinuria, but they do not result in the ‘wire-loop’ glomerular lesion seen in lupus nephritis. Pyelonephritis may also cause proteinuria, but it is an infectious process and would present with additional symptoms such as nitrites, leukocytes, and blood in the urine.

Renal Complications in Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) can lead to severe renal complications, including lupus nephritis, which can result in end-stage renal disease. Regular check-ups with urinalysis are necessary to detect proteinuria in SLE patients. The WHO classification system categorizes lupus nephritis into six classes, with class IV being the most common and severe form. Renal biopsy shows characteristic findings such as endothelial and mesangial proliferation, a wire-loop appearance, and subendothelial immune complex deposits.

Management of lupus nephritis involves treating hypertension and using glucocorticoids with either mycophenolate or cyclophosphamide for initial therapy in cases of focal (class III) or diffuse (class IV) lupus nephritis. Mycophenolate is generally preferred over azathioprine for subsequent therapy to decrease the risk of developing end-stage renal disease. Early detection and proper management of renal complications in SLE patients are crucial to prevent irreversible damage to the kidneys.